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Abstract
Background: Src family kinases (SFK) are implicated in the development of some colorectal
cancers (CRC). One SFK member, Lck, is not detectable in normal colonic epithelium, but becomes
aberrantly expressed in a subset of CRCs. Although SFK have been extensively studied in
fibroblasts and different types of immune cells, their physical and functional targets in many
epithelial cancers remain poorly characterised.
Results: 64 CRC cell lines were tested for expression of Lck. SW620 CRC cells, which express
high levels of Lck and also contain high basal levels of tyrosine phosphorylated (pY) proteins, were
then analysed to identify novel SFK targets. Since SH2 domains of SFK are known to often bind
substrates after phosphorylation by the kinase domain, the LckSH2 was compared with 14 other
SH2s for suitability as affinity chromatography reagent. Mass spectrometric analyses of LckSH2-
purified pY proteins subsequently identified several proteins readily known as SFK kinase
substrates, including cortactin, Tom1L1 (SRCASM), GIT1, vimentin and AFAP1L2 (XB130).
Additional proteins previously reported as substrates of other tyrosine kinase were also detected,
including the EGF and PDGF receptor target Odin. Odin was further analysed and found to contain
substantially less pY upon inhibition of SFK activity in SW620 cells, indicating that it is a formerly
unknown SFK target in CRC cells.
Conclusion: Rapid identification of known and novel SFK targets in CRC cells is feasible with SH2
domain affinity chromatography. The elucidation of new SFK targets like Odin in epithelial cancer
cells is expected to lead to novel insight into cancer cell signalling mechanisms and may also serve
to indicate new biomarkers for monitoring tumor cell responses to drug treatments.
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Background
Src family kinases (SFK) in human cancers
SFK play crucial roles in a wide range of human signalling
pathways and cell types. They are also implicated in sev-
eral human cancer types, including colorectal cancers [1].
For historical reasons, many studies looking at SFK signal-
ling and SFK-driven oncogenesis were initially done with
avian and mammalian fibroblasts and later on in a variety
of haematopoietic cells [2]. Much less is known about the
actions and targets of SFK in epithelial cells, which
account for the majority of human tumors. c-Src and
other SFK members appear to be rarely mutated in human
tumors, a fact that has led to their delayed recognition as
therapeutic targets for cancer treatments [3]. Further com-
plexity arises from the great heterogeneity of molecular
lesions found in human tumors [4], which is only now
becoming fully appreciated.
A recent study from our group with a large panel of
human CRC cell lines has shown that most, if not all CRC
cells require a basal SFK activity for proliferation and also
identified c-Met as a target of SFK in a subset of CRC cells
with highly active SFK [5]. Many other substrates of SFK
remain unknown. Further roles of SFK in CRC cell migra-
tion, invasion etc. have been described but are only par-
tially understood with respect to the molecular events that
occur (reviewed in [1]).
Nevertheless, inhibitors with SFK blocking activity are cur-
rently making their way into the clinic, for example as sec-
ond generation tyrosine kinase inhibitors for CML
therapy. In addition, several SFK inhibitor trials for solid
tumors like colorectal carcinomas are ongoing or in the
planning phase [6]. A better understanding of the roles
and effectors of SFK in CRC cells is therefore urgently
needed.
In order to learn more about SFK targets in CRC, we have
initiated a mass spectrometry based analysis of tyrosine
phosphorylated (pY) proteins using a panel of CRC cells.
In this pilot study we focus on SW620 cells which aber-
rantly express Lck and test the usefulness of SH2 domains
as affinity purification reagents. Our experiments show
that this is a viable technique to rapidly identify novel SFK
targets, which should also be applicable to many other
signalling systems that depend on tyrosine phosphoryla-
tion of proteins.
Results
Expression of Lck in a subset of CRC cells
A panel of 64 CRC cell lines (for further details on origins
see [5], supporting information Table 1) was analysed for
the expression of Lck by western blotting. Three lines with
substantial expression of Lck protein, namely NCI-H548,
SKCO-1 and SW620 cells, were detected (Figure 1). The
SW620 cell line, which is derived from a tumor lymph
node metastasis and contains particularly high levels of
pY proteins [5], was selected for further analyses. It is
noteworthy, that c-Src is not highly upregulated or acti-
vated in SW620 cells (see [5], supporting information
Fig.12 for details). The protein expression and kinase
activity status of other SFK has not yet been analysed com-
prehensively in these cells. To determine whether Lck is
not only upregulated in its expression but also activated in
SW620, these cells as well as SW480 cells, another cell line
derived from the same patients' primary tumor, were com-
pared for cell morphology (Additional file 1), Lck protein
expression, total phosphotyrosine levels, overall activa-
tion of SFK and Lck activity (Figure 2). Interestingly, Lck
protein expression is substantially higher in the metasta-
sis-derived SW620 cells. This is also echoed in the Lck
kinase activity, as indicated by Lck activation loop phos-
phorylation, as well as overall SFK activity and total tyro-
sine phosphorylation levels. However, whether Lck
upregulation and activation is a key event in driving the
development of tumor metastasis in some CRC remains
to be investigated.
Effective binding of phosphotyrosyl proteins from SW620 
to the LckSH2 domain
Src family kinases have been reported to initially phos-
phorylate substrates via their catalytic domain and to sub-
sequently bind to the newly generated phosphoepitope
via their SH2 domains, leading, at least in some cases, to
processive phosphorylation of multiple tyrosines [7]. SFK
SH2 domains could therefore be particularly useful tools
to effectively affinity-purify pY proteins that are substrates
of SFK. This assumption was tested subsequently with
total cell SW620 lysate. 15 SH2 domains derived from dif-
ferent signalling proteins were expressed as GST-fusion
proteins and used to precipitate pY proteins from SW620.
Western blotting with anti-pY antibody showed that the
LckSH2 precipitates a large number of pY proteins (Figure
3). Most other SH2 domains tested were less effective and
the LckSH2 domain was chosen for subsequent pY pro-
tein purifications. Since pY proteins comprise only a very
small fraction of cellular proteins, an additional cell frac-
tionation step was combined with SH2 domain affinity
purification step to isolate proteins for mass spectrometric
(MS) analyses. Comparison of pY protein levels in differ-
ent membrane fractions and cytosolic protein (S100)
indicated that the vast majority of detectable pY proteins
is found in the S100 (data not shown) and this fraction
was further investigated. Several batches of 15 to 60 mg
S100 protein were repeatedly pre-cleared with GST cou-
pled to GSH-sepharose beads and finally GSH-beads
alone to remove non-specific binding proteins and the
remaining supernatant was then incubated with GST-
LckSH2 beads. As a control, an equal amount of pre-
cleared S100 was incubated with bead-immobilised GST-Cell Communication and Signaling 2008, 6:7 http://www.biosignaling.com/content/6/1/7
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Aberrant expression of the Src family kinase Lck in three of sixty-four CRC cell lines Figure 1
Aberrant expression of the Src family kinase Lck in three of sixty-four CRC cell lines. 150 μg of total cell RIPA 
lysates (TCL) from each cell line were separated by SDS-PAGE and analysed for Lck expression by western blotting. 150 μg of 
TCL from the Jurkat T-cell line were also used as positive control.
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Comparison of SW480 and SW620 cells for overall pY levels, SFK activity, Lck expression and activity Figure 2
Comparison of SW480 and SW620 cells for overall pY levels, SFK activity, Lck expression and activity. Both cell 
lines are derived from the same patient. SW480 was established from the primary tumor, SW620 from a lymph node metasta-
sis. A – D: 20 μg of TCL from each cell line were separated by SDS-PAGE and western blots (WB) conducted with antibodies 
as indicated. Arrowheads in A indicate pY bands increased or only detectable in SW620 cells. The asterisk in C indicates a 
barely visible band that comigrates with the expected size of Lck. Actin levels were analysed as loading control in D. To deter-
mine the phosphorylation of Lck in the activation loop (results shown in E), which critically regulates Lck activity, 1 mg of TCL 
from each cell line was immunoprecipitated with anti-Lck mAb and probed with anti-pY419Src that cross-reacts with several 
SFK family members, including Lck, due to high conservation of this epitope (further details in [5]). An IgG control of the same 
isotype was also included to precipitate non-specific binding proteins from 1 mg of TCL of SW620 cells. Note that some of the 
molecular weight markers used do not run exactly accordingly to the indicated molecular weights of the marker proteins, pre-
sumably due to the coupling of dye molecules to them.
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Differential binding of pY proteins from SW620 cells to SH2 domains from 15 different signalling proteins Figure 3
Differential binding of pY proteins from SW620 cells to SH2 domains from 15 different signalling proteins. Top 
panel: 1 mg of TCL was precipitated with 50 μg of bead-immobilised GST-SH2 fusion protein, precipitates repeatedly washed 
with RIPA buffer and bound proteins analysed by anti-pY western blotting. Bottom panel: Coomassie blue staining of the affin-
ity purified GST-SH2 domain fusion proteins used for the precipitations. Approximately 10 μg of each protein was loaded onto 
the gel to analyse protein purity and integrity.
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LckSH2, which had been pre-incubated with an excess of
a phosphopeptide (EPQpYEEIPI; originally derived from
hamster middle T antigen) that binds with high affinity to
the pY binding pocket of the LckSH2 domain [8,9], or
GSH beads alone. Bound proteins were detected with
Coomassie Blue staining. A representative example is
depicted in Figure 4. These experiments showed that most
of the SW620 S100 proteins that interact with the LckSH2
require indeed the pY binding pocket of this domain. The
gel lanes containing the proteins precipitated with GST-
LckSH2 in the absence of pY peptide were subsequently
cut into 10 slices, which were subjected to tryptic digest
and MS analyses. The proteins identified through this
approach are listed in Additional file 2.
LckSH2 affinity chromatography allows rapid mass 
spectrometric identification of numerous tyrosine kinase 
substrates
Notably, many of the proteins identified are readily
known as substrates of protein tyrosine kinases. Previ-
ously detected phosphosites for the MS-identified pro-
teins were extracted from the PhosphoSitePlus™ database
http://www.phosphosite.org and are also listed in Addi-
tional file 2. As this database is constantly updated and
several other phosphoprotein databases exist, this listing
is expected to underestimate the number of actual pY sites
and pY proteins that were previously reported. Cortactin,
a prominent SFK substrate [10], appeared as a major hit in
several gel slices, which could be a consequence of differ-
ential splicing, the presence of posttranslational modifica-
tions or proteolytic processing in SW620 cells. The
AceView program http://www.ncbi.nlm.nih.gov/IEB/
Research/Acembly/ predicts numerous putative isoforms
for cortactin, but the splice-variants occurring in colonic
epithelium or colorectal cancers have not yet been
reported. Other known SFK substrates identified were
vimentin [11,12], 3BP-2 (SH3BP2) [13], GIT1 [14],
Tom1L1 [15] and AFAP1L2/XB130 [16]. The adaptor pro-
tein CRKL, the major target of the Bcr-Abl oncogene [17],
a tyrosine kinase activating SFK in CML cells, was also
detected. Other proteins found by MS, for example
MAP1B, have only a marginal publication history of tyro-
sine phosphorylation, but contain multiple pY residues
according to a publicly accessible databases http://
www.phosphosite.org. Yet others, like sorbitol dehydro-
genase, are not yet established as tyrosine kinase targets
but have been reported to regulate tyrosine kinase signal-
ling [18]. Somewhat surprisingly, we did not find in our
experiments some well-studied Src substrates like focal
adhesion kinase (FAK), p130Cas/BCAR1 or p70 paxillin,
which were initially reported as SFK substrates in fibrob-
lasts. If this is due to technical limitations or whether
these proteins are actually not SFK targets in SW620 cells
remains to be determined.
Comparison of SW620 cytosolic proteins binding to LckSH2  versus LckSH2 pre-blocked with a high affinity binding pY  peptide Figure 4
Comparison of SW620 cytosolic proteins binding to 
LckSH2 versus LckSH2 pre-blocked with a high affin-
ity binding pY peptide. Cytosol (S100) of SW620 cells 
was pre-cleared several times with GST immobilised on GSH 
beads to reduce non-specific protein binding. Supernatants of 
these pre-clearings corresponding to 20 mg of S100 were 
then incubated with bead-immobilised GST-LckSH2 or GST-
LckSH2 pre-blocked with the peptide EPQpYEEIPI, or 
unloaded GSH beads to detect potentially remaining non-
specific protein binding and, after washing repeatedly with 
RIPA buffer, separated by SDS-PAGE and stained with colloi-
dal dye (Roti-Blue). The GST-LckSH2 precipitation lane was 
subsequently processed for MS identification of bound pro-
teins.
GSH
beads LckSH2
LckSH2
+
EPQpYEEIPI
220 -
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Some examples of frequent 'false positives' found in many
MS experiments (see also [19] for discussion) are under-
lined in the table. However, it should be noted that many
of these proteins, for example tubulins and β-actin, have
actually been reported to be tyrosine phosphorylated by
SFK [20,21], so it is by no means certain or even likely that
all of these proteins are non-specifically interacting with
the SH2 domain affinity matrix.
Odin is a target of SFK in CRC cells
From the marginally characterised pY proteins found by
mass spectrometry that are not known SFK substrates, the
Odin protein was selected for further experimental inves-
tigation. Odin has been first described as a target and sig-
nal transmitter of receptor tyrosine kinases like EGFR and
PDGFR [22] and more recently as an interaction partner
of the receptor tyrosine kinase EphA8 [23]. Odin reduc-
tion by siRNA diminishes ephrinA5-induced effects like
cell migration in HEK293 cells and neurite retraction in
Neuro2a cells.
As expected, Odin was precipitated with the Gst-LckSH2.
It also bound, to a lesser degree, to FynSH2, but not
SrcSH2 or GST alone (Additional file 3). The functions of
Odin in CRC are yet unknown and we have so far failed to
see a direct complex formation of Odin and EphA8 in
SW620 cells (data not shown). Immunoprecipitation of
Odin with a specific antiserum and subsequent immuno-
blotting with anti-pY mAb showed that Odin is tyrosine
phosphorylated. Treatment of SW620 cells with the SFK
inhibitor PP2 [24,25], but not compound solvent alone,
greatly reduced the detectable tyrosine phosphorylation
of Odin, indicating that Odin is a SFK substrate, or a sub-
strate of another tyrosine kinase that is regulated by SFK
(Figure 5). SU6656, and Src-1, two other small molecule
SFK inhibitors [25,26] were also tested, but found to be
much less potent than PP2 in reducing overall pY levels in
SW620 cells and did not effectively inhibit Odin tyrosine
phosphorylation (not shown). We also tested the PP2-
related inhibitor compound PP3 (4-amino-7-phenylpyra-
zol [3,4-d]pyrimidine) which does not inhibit SFK, but
affects the EGF receptor [27] and did not observe a reduc-
tion of pY Odin (data not shown).
Discussion
Relatives and functions of Odin
Odin belongs into the small family of ANKS proteins that
contains, apart from Odin (ANKS1A, KIAA0229, formerly
a.k.a. ANKS; gene on chromosome 6p21.31), only one
other member, ANKS1B (a.k.a. EB-1, AIDA-1 [AIDA-1a
and AIDA-1b isoforms], cajalin-2, ANKS2; gene on chro-
mosome 12q23.1). Odin and AIDA-1B are most closely
related and share a similar structure. Odin contains mul-
tiple ankyrin repeats near its N-terminus as well as two
SAM domains and, in the C-terminal half of the protein, a
PTB (PID) domain, which belongs to the Dab-like sub-
type of PTBs [28]. These domains are connected by an
intermediate region with no obvious structural elements,
which harbours the majority of currently known phos-
phorylation sites. Two Odin pY sites have been repeatedly
reported, namely pY454 and pY833 [29-32], but if and
how they regulate Odin function, or which kinases are
responsible for which site, remains unclear.
From its structure, Odin appears to be an adaptor protein,
presumably coupling receptors like EGFR, PDGFR and
EphA8 to their downstream signalling machinery. The
roles of Odin in CRC, if any, remain to be elucidated.
Knockdown of Odin in CRC cells with RNA interference
may give further insight. However, RNA interference anal-
yses of CRC cells using transient transfection with syn-
Treatment of SW620 cells with the SFK inhibitor PP2 abol- ishes the tyrosine phosphorylation of Odin Figure 5
Treatment of SW620 cells with the SFK inhibitor 
PP2 abolishes the tyrosine phosphorylation of Odin. 
SW620 cells were treated with 30 μM of the SFK inhibitor 
PP2 dissolved in DMSO or 0.06%(v/v) DMSO for 24 h, then 
lysed and subjected to immunoprecipitation with anti-Odin 
or normal rabbit IgG (contr. IgG) as indicated. pY protein 
was detected by western blotting with anti-pY mAb. 10 μg of 
untreated SW620 TCL were also analysed. The blot was sub-
sequently stripped and reprobed to detect Odin. The black 
arrowheads indicate the Odin bands, the open arrowhead 
points to a protein that binds non-specifically to control IgG 
beads and is equally affected by PP2 treatment of the SW620 
cells.
WB: pY (4G10)
IP: Odin
D
M
S
O
P
P
2
C
o
n
t
r
.
 
I
g
G
T
C
L
220 -
97 -
220 -
97 -
WB: OdinCell Communication and Signaling 2008, 6:7 http://www.biosignaling.com/content/6/1/7
Page 8 of 11
(page number not for citation purposes)
thetic oligonucleotides are so far technically challenging
and optimisation experiments are ongoing. Alternatively,
transfection with shRNAs and selection of stable clones
can be attempted, but this may lead to biased results,
especially if Odin would be involved in regulating cell
proliferation and/or survival, unless a system with tightly
regulatable RNA interference is used.
It also remains to be investigated which receptors are cou-
pled to Odin in CRC cells and whether these are linked to
SFK. In a previous study we have documented a connec-
tion between the HGF receptor, c-Met, and SFK, namely
an activation of c-Met by SFK. From our current analysis,
we cannot exclude that Odin is an indirect target of SFK
and, for example, directly phosphorylated by c-Met. Co-
immunoprecipitations aiming to detect potential c-Met
and Odin complexes and inhibition of c-Met kinase activ-
ity with specific compounds are obvious experiments to
be included in follow-up studies.
Odin as a potential biomarker for monitoring SFK inhibitor 
activities in vivo
Odin phosphorylation could also be explored for its use-
fulness as a clinical marker in monitoring the effectiveness
of SFK inhibitors currently used in trials with CRC
patients, if highly specific Odin phosphoepitope antibod-
ies can be generated. This is, however, not a trivial matter
since antibody cross-reactivity is a big problem for tissue
stainings, especially when looking at protein modifica-
tions like phosphorylation. Approximately 520 kinases
are encoded in the human genome and as much as one
third of all cellular proteins are believed to contain phos-
phoresidues. Many of these kinase substrate proteins
come in multiple splice variants, creating additional com-
plexity. The average kinase has been estimated to have
around different 20 substrate proteins with an even
greater number of substrate epitopes. In many cases, the
substrates of a specific kinase will have substantial amino
acid similarity in the kinase-targeted epitopes, making it
likely that polyclonal phosphoepitope antibodies gener-
ated against a specific site will cross-react at least to some
degree with other substrate epitopes of the same kinase.
Generation of mAbs against a phospho-epitope of interest
can sometimes, albeit not always, reduce or eliminate
cross-reactivity problems. Another approach to overcome
cross-reactivity problems is the use of FRET [33] or similar
methods, but these techniques are still under develop-
ment and not yet part of the tool repertoire routinely used
in clinical practice.
Identification of additional tyrosine targets in epithelial 
cancer cells and beyond
Since cellular protein – protein interactions depending on
pY-containing epitopes are predominantly mediated by
SH2 domains, we have explored in this pilot study their
usefulness for the rapid MS identification of novel tyro-
sine kinase targets in CRC cells. Approximately 120 SH2s,
which differ considerably in their pY-epitope binding
selectivity, have been recognised in the human genome to
date [34,35]. A subset of PTB domains and the C2 domain
of PKCdelta have also been reported to bind to specific
pY-containing epitopes in cells [28,36]. Of the 120 exisit-
ing human SH2 domains, over 80 can be expressed in bac-
teria and are also already functionally validated [34,37].
Together with a much smaller set of PTBs, they should
become a valuable resource to quickly identify many
novel substrate proteins in tyrosine kinase-driven cancers
and many other diseases. SH2 domain-based affinity
matrices may even prove to be more effective than current
standard affinity purifications relying on anti-pY mAbs
and they could potentially also preferentially enrich for
proteins with biologically relevant modifications.
Beyond this, and taking into consideration the current
pace of advances in MS techniques, even the identification
of whole SH2 interactomes representing a systematic anal-
ysis of all binding partners for SH2 domains in a specific
organism may be lurking just behind the horizon.
Conclusion
SH2 domain-based affinity chromatography combined
with MS analysis allows for the rapid identification of
tyrosine kinase targets in human cancer cells, which
should facilitate the elucidation of new signalling mecha-
nisms, support the identification of new biomarker candi-
dates and potentially even point to novel therapeutic
targets. In the current study, the adaptor protein Odin was
identified as a new SFK target in CRC cells that can now be
analysed for a potential role in CRC development.
Methods
CRC lines, total cell lysates and cytosolic extracts
Cell line origins, culture conditions and total cell protein
extract preparations of 64 CRC lines with RIPA buffer [20
mM TrisHCl pH 7.5, 100 mM NaCl, 1 mM EDTA, 1% Tri-
ton X-100, 0.5% deoxycholic acid, 0.1% SDS; supple-
mented with 2× Complete™ protease inhibitor mix
(11697498001; Roche) and phosphatase inhibitor cock-
tails 1 and 2 (P2850 and P5726; Sigma)] were previously
described [5]. SW480 cells (origin: ATCC) are derived
from the same patient from which SW620 cells were
made. SW480 were established from the primary tumor,
SW620 from a lymph node metastasis [38]. To prepare the
cytosolic extracts (S100) from SW620, cells were washed
thrice with chilled PBS and once with hypotonic lysis
buffer [HLB; 10 mM TrisHCl (pH 7.5), 10 mM KCl, 1 mM
EDTA, 1 mM EGTA, 2 mM MgCl2, 1 mM DTT, supple-
mented with 2× Complete™ protease inhibitor mix and
phosphatase inhibitor cocktails 1 and 2 (P2850 and
P5726)] and then scraped and fully lysed by dounceCell Communication and Signaling 2008, 6:7 http://www.biosignaling.com/content/6/1/7
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homogenization in HLB. The homogenate was then clari-
fied by high-speed centrifugation (1 h, 100,000 × g, 4°C)
to obtain S100, which was snap-frozen with liquid nitro-
gen in aliquots and stored at -80°C until further use. Pro-
tein concentrations were determined by the Bradford
method [39].
Expression and purification of GST-SH2 fusion proteins
The production of GST and different GST-SH2 fusion pro-
teins [GST-AblSH2, GST-CrkLSH2, GST-FynSH2, GST-
GapSH2 (N-terminal), GST-GrapSH2, GST-LckSH2, GST-
Mona(Gads)SH2, GST-NckSH2, GST-PI3KSH2 (C-termi-
nal), GST-PLCgammaSH2 (N-terminal), GST-ShcSH2,
GST-SrcSH2, GST-Shp2SH2 (C-terminal), GST-
TensinSH2 and GST-Vav1SH2] was described previously
[40-43]. Briefly, after affinity purification on GSH-sepha-
rose, elution with free GSH and three-fold dialysis in 5
mM TrisHCl (pH 7.5) to remove GSH, protein concentra-
tions were determined by Bradford assay and protein
purity and integrity analysed by SDS-PAGE followed by
staining with Coomassie Blue (Brilliant Blue R, B-0630;
Sigma).
Western blots and immunoprecipitations (IPs)
Western blotting of proteins was done as essentially previ-
ously described [5]. Anti-Lck (mAb 3A5) was from Santa
Cruz Biotechnology (sc-433). pY proteins were detected
with anti-pY mAb (4G10). 1 μg of anti-Odin (rabbit pol-
yclonal, ST1039; Calbiochem) was used for IP using 1 mg
of total cell RIPA protein extract incubating with 20 μl of
protein A beads overnight at 4°C. Normal rabbit IgG (sc-
2027) was used for control IPs. Lck IPs were done with 4
μg anti-Lck mAb for 1 mg of total cell RIPA protein extract.
An equal amount of anti-FLAG mAb (M2; Kodak) was
used as IgG isotype control. Both mAb were captured with
protein G beads. Anti-pY419Src (polyclonal rabbit, 2101;
Cell Signaling Technology) reacts with all members of the
SFK family expressed in CRC cells due to high conserva-
tion of the target epitope (for further details see [5]). It
was used to simultaneously analyse multiple family mem-
bers in total cell lysates, or to specifically investigate Lck
phosphorylation in the kinase activation loop after Lck IP.
Cell extracts were also probed for actin (mAb, A3853;
Sigma-Aldrich) as a loading control. Molecular weight
standards used were from GE Healthcare (RPN756 and
RPN800E).
Treatment of SW620 cells with kinase inhibitors
SW620 cells were incubated with 30 μM SFK inhibitor
PP2 (529573; Calbiochem) dissolved in DMSO, or the
structural analogue PP3, which lacks SFK inhibitory activ-
ity (529574; Calbiochem), or with the compound solvent
(D2650; Sigma-Alrich) alone for 24 h. Cells were then
harvested by lysing in RIPA buffer [5] and protein concen-
trations determined by Bradford assay.
Precipitation assay with GST-SH2 domains
GST-SH2 precipitation assays to analyse pY protein bind-
ing were done at 4°C with total cell RIPA lysates. 1 mg of
protein extract was mixed in each case with GSH beads
loaded with either 50 μg GST or GST-SH2 fusion protein.
After nutating in the cold overnight, beads with captured
proteins were washed 4 times with chilled RIPA buffer [5]
and bound proteins separated by SDS-PAGE. After trans-
fer to PVDF membrane, pY proteins were visualized by
immunoblotting with anti-pY mAb.
Enrichment of pY proteins for mass spectrometry analysis
S100 (5–20 mg per sample) was initially precleared with
100 μl of GSH beads pre-coupled with 200 μg of GST for
3 hours at 4°C, after which beads were spun down and
supernatants were recovered. This procedure was then
repeated once, after which the supernatant was pre-
cleared once more with empty GSH beads to remove
traces of GST, presumed to have leaked off previously. Pre-
cleared S100 was then incubated overnight with GSH
beads loaded either with 100 μg GST-LckSH2 or 100 μg
GST-LckSH2 pre-incubated overnight with 100 μg of
EPQpYEEIPI peptide (amidated at C-terminus, HPLC-
purified). The beads were then washed four times with
chilled RIPA buffer and samples subjected to SDS-PAGE.
After electrophoresis, the gels were stained with Coomas-
sie Brilliant Blue R, or Roti-Blue Colloidal Coomassie
staining (Carl Roth, Germany) according to manufac-
turer's instruction.
Identification of SH2-interacting proteins by tandem mass 
spectrometry
The gel region containing proteins of ca. 45 kDa or more
were excised cut into 10 separate slices representing dis-
tinct molecular weight regions and subjected to in-gel
trypsin digestion as previously described [44]. Digested
protein material was kept at 4°C until analysis. Sample
analysis was performed by LC-MS/MS using an Ultimate™
(LC-Packings, Dionex, Amsterdam, NL) HPLC system
coupled on-line to a 3D high-capacity ion trap (HCT-
plus™, Bruker Daltonics, Bremen, Germany) mass spec-
trometer via a pneumatically assisted nano-electrospray
source as described previously [45]. MS/MS spectra (peak
lists) were searched against the SwissProt (release 54.0,
07/2007, number of entries 276256) or trEMBL (release
37.0, 07/2007) databases using Mascot version 2.2
(Matrixscience, London, UK) and the following parame-
ters: peptide tolerance 2.5 Da, 13C=0, fragment tolerance
0.8 Da, missed cleavages: 3, instrument type: ESI-TRAP.
The interpretation and presentation of MS/MS data was
performed according to published guidelines [46]. In
addition, individual MS/MS spectra for peptides with a
Mascot Mowse score lower than 40 (Expect <0.015) were
inspected manually and included in the statistics only if a
series of at least 4 continuous y or b ions were observed.Cell Communication and Signaling 2008, 6:7 http://www.biosignaling.com/content/6/1/7
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Protein ID is also based on the assignment of at least two
peptides. In cases where proteins were identified based on
one peptide sequence, the corresponding MS/MS spectra
were inspected and verified manually.
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